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Abstract 
 
      Compound Kushen Injection (CKI) is Sophora Flavescens and Heterosmilacis Japonicae extract. Meta-analysis 
confirmed that CKI plus transcatheter arterial chemoembolization (TACE) is more superior to TACE alone for unresectable 
hepatocellular carcinoma (UHCC) patients. 
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The list of abbreviations: CKI=Compound Kushen Injection; TACE= transcatheter arterial chemoembolization; 
UHCC=unresectable hepatocellular carcinoma; WHO=World Health Organization; SD rat=Sprague Dawley Rat; OR=Odds 
Ratio; CI=Confidence Interval; KPS=Karnofsky Performance Score. 
 
 
Introduction 
 
     Hepatocellular carcinoma is one of the commonest forms of malignancies. Its global morbidity ranks the seventh, 
while mortality is at fourth position in the world. Statistics from the World Health Organization (WHO, 2008) show that 
749,744 cases of hepatocellular carcinoma were diagnosed, of these, 695,726 cases died in 2008. Southern Africa, Southeast 
Asia and the Mediterranean coast is the high incidence area of hepatocellular carcinoma. Hepatocellular carcinoma has been 
the second leading cause of death by cancer in China, there were 372,079 deaths in 2008 (Ferlay et al., 2008). However, due 
to the spread of hepatitis B, the incidence and mortality of hepatocellular carcinoma also show a rising trend (Liaw et al., 
1986 ). 
          For unresectable hepatocellular carcinoma (UHCC) patients, most of them are at an advanced stage, few 
meaningful therapeutic options are available (Bruix et al., 2002). TACE is considered as a primary and complementary 
measure for the treatment of UHCC (Roche et al., 2003; Stuart, 2003; Venook et al., 1990). However, the adverse events of 
TACE, such as post embolization syndrome, hepatic insufficiency and myelosuppression, are frequent leads to interruption of 
TACE treatment (Chung et al., 1996). As a result, searching new drugs which can combine with TACE to enhance the 
therapeutic effects and reduce its adverse events has become a hotspot. 
          Many clinical trials showed that CKI plus TACE can reduce the adverse reactions and improve quality of life for 
UHCC (Chen, 2009; Tong, 2010; Zhang et al., 2006; Zhu and Li, 2006). CKI was extracted from the mixture of Sophora 
flavescens and Heterosmilacis Japonicae with the mass ratio of 7 than 3. Experimental studies confirmed that CKI has 
significant killing effect on the tumor cells, such as Hep, H22, LAC and Lewis in vitro (Lin et al., 2009). Meanwhile, animal 
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experiment showed that CKI can depress the growth of hepatocellular carcinoma and its angiogenesis in SD rat (Sprague 
Dawley Rat) (Li et al., 2007; Zhu et al., 2011). These results revealed that CKI may enhance the therapeutic effects of TACE. 
Until now, however, rigorously designed, randomized, large, multi-center, double-blind, controlled trials for UHCC have not 
been reported. 
           The purpose of this meta-analysis is to evaluate whether CKI enhances therapeutic effects for UHCC after 
TACE. It is anticipated that this systematic review will provide evidence-based information for clinical practice. 
 
 
Materials and Methods 
Criteria for Inclusion and Exclusion 
 
            The articles were read by two reviewers (Qizhe Sun and Yuan Gao) and studies were selected systematically 
according to the following criteria: (1) hepatocellular carcinoma patients were confirmed cytologically or pathologically, or 
diagnosed by CT; (2) trials were described as randomized clinical trials (RCTs); (3) published trials included a treatment 
group receiving CKI plus TACE and a control group receiving TACE; and (4) the published data of primary interest were 
tumor response and quality of life for calculation of the odds ratio (OR) at a 95% confidence interval (CI). Trials were 
excluded if they did not meet the criteria above and included the following: (1) involved animal studies or in vitro studies; (2) 
did not represent primary research (review articles, letters to the editor, etc); or (3) represented duplicate publications of other 
studies previously identified in our systematic evaluation. 
 
Literature Search Strategy 
 
           Retrieval of trials was performed through the Cochrane Database of Systematic Reviews (The Cochrane 
Library, Issue 5, 2011), CENTRAL (the Cochrane Central Register of Controlled Trials, January 1966 to May 2011), 
MEDLINE (January 1966 to May 2011), EMBASE (January 1966 to May 2011), CNKI (Chinese National Knowledge 
Infrastructure, January 1979 to May 2011) and CBMdisk (Chinese Biomedical Database, January 1978 to May 2011). All 
searches were performed without language limitations to identify all relevant trials. The main search terms were:  
hepatocellular carcinoma， hepatic tumor, hepatic cancer， liver cancer， or liver tumor and transcatheter arterial 
chemoembolization, TACE transcatheter arterial embolization or TAE and Compound Kushen Injection, Yan Shu, Kushen, 
Sophora flavescens or Sophorae. The search results were downloaded to a reference database and screened further.  
 
Outcome Measurements 
 
           The main outcome measurements were as follows: (1) Tumor response was evaluated according to the WHO 
standard for evaluating therapeutic efficacy on solid tumors (Therasse, 2002). Based on the degree of tumor regression, 
efficacy was evaluated as following: CR (complete response, CT and/or MRI revealed complete clearance of the lesion); PR 
(partial response, lesion decreased more than 50%); SD (lesion decreased less than 50% or increased less than 25%); PD (size 
of lesion increased more than 25% after treatment). Tumor responses were defined as CR+PR. (2) Quality of life was 
evaluated according to the Karnofsky performance score (KPS) (Yates et al., 1980), which was classified as: Improvement 
(KPS improved ≥10 points after treatment)；Stabilization (KPS improved ＜10 points or decreased ＜10 points); 
Deterioration (KPS decreased ≥10 points after treatment). (3) One-year survival. (4) Adverse events were evaluated, based 
on the WHO criteria for evaluation of acute and subacute toxic and adverse reactions (Miller et al., 1981).  
 
 
Sun et al., Afr J Tradit Complement Altern Med. (2012) 9(2):178-188 180
Review Methods 
Data extraction  
 
           The trials selection and the data extraction were performed independently by two investigators. For conflicts, an 
agreement was reached by discussion among reviewers. The following information was collected from each study: (1) the 
information about patients (the number of patients allocated, clinical stage, and KPS); (2) the characteristics of methods (the 
randomization procedure, concealment of allocation, blinding procedure, withdrawal and reasons, and protection against 
contamination); (3) The characteristics of interventions (dosage and duration of therapy, TACE course, and any 
co-interventions; (4) the outcomes (tumor response, quality of life, one-year survival and adverse events). 
 
Quality assessment  
 
            Methodological quality was evaluated according to the Cochrane Handbook for Systematic Reviews of 
Interventions (Version 5.1.0) (Higgins et al., 2011). The evaluation was performed in the following aspects: (1) selection bias 
(random sequence generation and allocation concealment); (2) performance bias (blinding of participants and personnel); (3) 
detection bias (blinding of outcome assessment); (4) attrition bias (incomplete outcome data); (5) reporting bias (selective 
reporting); (6) other bias (other sources of bias). The judgement of each term was assigned as: ‘Low risk’ of bias (the 
description of methods are adequate and the procedures are correct), ‘High risk’ of bias (the methods or procedures are 
improper), or ‘Unclear risk’ of bias (without description of methods and procedures). The methodological quality evaluation 
was performed independently by two reviewers, and discrepancies were resolved through discussion. 
 
Statistical method.  
 
            Meta-analysis was performed according to recommendations from the Cochrane Handbook for Systematic 
Reviews of Interventions (Higgins et al., 2011) using the statistical software RevMan5.1.2 (Update Software Ltd, Oxford, 
England) provided by the Cochrane Collaboration. Statistical heterogeneity was explored using the x2 test (P<0.10 was 
considered representative of significant statistical heterogeneity). The random-effects model was used when there was 
significant statistical heterogeneity (P<0.10); otherwise the fixed-effects model was used. For dichotomous variables, OR 
(Odds Ratio) with 95%CI was calculated. Patients with incomplete or missing data were counted as treatment failures. The 
sensitivity analysis was performed by comparing the results of two different statistical models (random-effects model and 
fixed-effects model). Potential publication bias was examined by funnel plot. 
 
 
Results 
Common characteristics 
 
            The initial search identified 795 trials for possible inclusion in the review, but all of these trials were reported 
in Chinese journals. According to the inclusion criteria, 785 trials were excluded as obvious error, non-clinical studies, 
duplicates, or study objectives different from the aim of this review. Ultimately, 10 trials (Cao et al., 2009; Chen et al., 2006; 
Chen et al., 2007; Deng et al., 2009; Guan et al., 2006; Huang et al., 2006; Wang and Cheng, 2009; Xu et al., 2010; Yang, 
2006; Yu and Kang, 2009) were identified for further study (726 patients), but without a multi-center study. Characteristics 
of the included trials are listed in Tables 1 and 2. 
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Table 1: Characteristics of Included Trials 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                              aKPS, Karnofsky Performance Scale; bTACE, transcatheter arterial chemoembolization; 
Study No. Enrolled Patients Stage KPSa Treatment vs Control Outcomes 
Author (year) Treatment Control  Treatment Control   
Cao et al., 2009 30 30 II, III ≥60 ≥60 TACE-Kushen vs TACE Tumor response, KPS, and adverse events 
Chen et al., 2006   16 14 II, III ＞50 ＞50 TACE-Kushen vs TACE Tumor response, KPS, and adverse events 
Chen et al., 2007 46 40 II, III ≥70 ≥70 TACE-Kushen vs TACE Tumor response, KPS, survival, and adverse events 
Deng et al., 2009 20 20 II, III ≥70 ≥70 TACE-Kushen vs TACE Tumor response, KPS, and adverse events 
Guan et al., 2006 58 59 II, III ＞50 ＞50 TACE-Kushen vs TACE Tumor response, KPS, survival, and adverse events 
Huang et al., 2006 35 33 II, III ≥50 ≥50 TACE-Kushen vs TACE Tumor response, KPS, and adverse events 
Wang et al., 2009 27 30 II, III ≥70 ≥70 TACEb-Kushen vs TACE Tumor response, KPS, and survival 
Xu et al., 2010 53 53 II, III — — TACE-Kushen vs TACE Tumor response, KPS, survival, and adverse events 
Yang, 2006 33 33 II, III ≥60 ≥60 TACE-Kushen vs TACE Tumor response, KPS, and survival 
Yu et al., 2010 48 48 II, III ＞60 ＞60 TACE-Kushen vs TACE Tumor response, KPS, and adverse events 
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Table 2: Compound Kushen Injection and Transcatheter Arterial Chemoembolization Drugs Used in Included Studies 
 
 
5-Fu=fluorouracil, DDP=cisplatin, ADM=Adriamycin, CF=Calcium Folinate, EPI=Epirubicin, MMC=Mitomycin, THP-ADM=pirarubicin hydrochloride, CBP=carboplatin, HCPT=Hydroxycamptothecin, LP=Lipiodol, GS=Gelatin sponge, Na=not described, D=days, I.v.drip=intravenous drip, I.v.c.infusion=   
intravenous continuous infusion. 
Study Anticancer Drug Embolizing Duration Compound Kushen Injection   Injection  
Author (year)  LP Agents Adjuvant Drug Days Dosage Method 
Cao et al., 2009 5-Fu, DDP, MMC Yes GS particles MMC 56<D<224 given 20ml per time, once daily over 14 days; began in the TACE operation day; I.v.drip 
Chen et al., 2006 5-Fu, DDP, EPI,  Na Na Na 63 given 20ml per time, once daily over 21 days; begin in the TACE operation day; I.v.drip 
Chen et al., 2007 5-Fu, MMC, EPI, Yes Na Na 84<D<126 given 20ml per time, once daily over the whole duration; I.v.drip 
Deng et al., 2009 THP-ADM Yes Na Na 61 given 20ml per time, once daily over 14 days; begin in the 2nd day after TACE operation; I.v.c. infusion 
Guan et al., 2006 (5-Fu, DDP, ADM) or (THP-ADM,5-Fu, CBP) Na Na Na 45<D<60 given 20ml per time, once daily over the whole duration; I.v.drip 
Huang et al., 2006 5-Fu, ADM, HCPT Yes Na Na 56<D<224 given 15~30ml per time, once daily over 10~20 days; begin in the TACE operation day; I.v.drip 
Wang et al., 2009 5-Fu, DDP, ADM Yes GS particles Na 140<D<168 given 20ml per time, once daily over 10 days; begin in the TACE operation day; I.v.drip 
Xu et al., 2010 5-Fu, DDP,CF Yes Na THP-ADM or HCPT 60<D<120 given 20ml per time, once daily over 15 days; begin in the 3rd day before TACE operation; I.v.drip 
Yang, 2006 DDP, MMC, ADM Yes GS particles Na 40<D<240 given 20ml per time, once daily over 20 days; began in the TACE operation day; I.v.drip 
Yu et al., 2010 5-Fu, ADM, HCPT Yes GS particles Na 84 given 20ml per time, once daily over 15 days; begin in the TACE operation day; I.v.drip 
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In terms of quality, all trials mentioned “randomization,” but none stated the generation of a random allocation sequence. 
No trials described information on allocation concealment and blinding. No trials reported the withdrawals and dropouts. 
(Figure 1) 
 
Figure 1: Quality of all included trials 
a. Risk of bias percentage graph of all included studies 
b. Risk of bias summary of all included studies 
Meta-analysis Outcomes 
Tumor response 
 
     Ten trials (726 patients) (Cao et al., 2009; Chen et al., 2006; Chen et al., 2007; Deng et al., 2009; Guan et al., 
2006; Huang et al., 2006; Wang et al., 2009; Xu et al., 2010; Yang, 2006; Yu et al., 2009) were identified with a CR+PR 
outcome measurement of tumor response. The fixed-effects model was used because of heterogeneity of the results of trials 
(Heterogeneity: Chi2=4.74, df=9 (P=0.86); I2=0%). The pooled analysis showed that compared with TACE alone, CKI plus 
TACE significantly improved the tumor response (OR=2.01; 95% CI [1.47, 2.74]; P < 0.0001) (Figure 2). 
Sun et al., Afr J Tradit Complement Altern Med. (2012) 9(2):178-188 184
 
Figure 2: Meta-analysis of tumor response. 
Compound Kushen Injection (C.K.I.) plus transcatheter arterial chemoembolization (TACE) versus TACE alone for tumor 
response (CR+PR) of patients with unresectable hepatocellular carcinoma. 
 
Quality of life 
 
    There were 9 trials (Cao et al., 2009; Chen et al., 2006; Chen et al., 2007; Guan et al., 2006; Huang et al., 2006; 
Wang et al., 2009; Xu et al., 2010; Yang, 2006; Yu et al., 2009) contained a KPS improvement of >10 points. The 
fixed-effects model was used (Heterogeneity: Chi2=5.51, df=8 (P=0.70); I2=0%). The results showed that CKI plus TACE 
significantly improved KPS (OR=2.47; 95% CI [1.77, 3.44]; P < 0.00001) (Figure 3). 
 
Figure 3: Meta-analysis of quality of life improvement.  
Compound Kushen Injection (C.K.I.) plus transcatheter arterial chemoembolization (TACE) versus TACE alone for KPS 
(>10 points) of patients with unresectable hepatocellular carcinoma. 
 
One-year survival 
 
     Five trials (432 patients) (Chen et al., 2007; Guan et al., 2006; Wang et al., 2009; Xu et al., 2010; Yang, 2006;) 
were identified with the outcome measurements of one-year survival. The fixed-effects model was used (Heterogeneity: 
Chi2=1.92, df=4 (P=0.75); I2=0%). The meta-analysis showed that CKI plus TACE significantly improved one-year survival 
(OR= 2.16; 95% CI [1.45, 3.23]; P=0.0002) (Figure 4). 
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Figure 4: Meta-analysis of one-year survival.  
Compound Kushen Injection (C.K.I.) plus transcatheter arterial chemoembolization (TACE) versus TACE alone for one-year 
survival of patients with unresectable hepatocellular carcinoma. 
 
Adverse Effects 
 
    We found 8 trials (Cao et al., 2009; Chen et al., 2006; Chen et al., 2007; Deng et al., 2009; Guan et al., 2006; 
Huang et al., 2006;  Xu et al., 2010; Yu et al., 2009) mentioned adverse events. All of the eight trials reported that the 
common symptoms such as abdominal pain, abdominal distension, diarrhea, hepatic insufficiency, and bone marrow 
depression were found in both groups. These might be due to the complications of TACE. There were six trials (Cao et al., 
2009; Chen et al., 2006; Chen et al., 2007; Huang et al., 2006;  Xu et al., 2010; Yu et al., 2009) showed that compared with 
TACE alone, CKI plus TACE significantly reduced the complications of TACE. In addition, two trials (Deng et al., 2009; 
Guan et al., 2006) reported that no adverse events attributable to CKI were observed. Therefore, we concluded that the use of 
CKI has no significant adverse events. 
 
Sensitivity Analysis 
 
    Sensitivity analysis was performed by comparing fixed-effects versus random- effects. In the primary analysis, 
outcome on quality of life was applied to the fixed-effects model (OR=2.47; 95% CI [1.77, 3.44]; P < 0.00001). Therefore, a 
random-effects model was used to re-analyzed it (OR= 2.45; 95% CI [1.75, 3.43]; P < 0.00001). The results were virtually 
identical. 
 
Publication Bias 
 
    We used the funnel plot to access the publication bias of literatures (Figure 5). The shape of the funnel plots 
seemed symmetric, and suggesting there was no obvious publication bias. 
 
 
DISCUSSION 
 
    Experimental studies Show CKI can significantly enhance the apoptosis rates of HepG2 cells and inhibit its 
transition from G2 phase to M phase in vitro. Therefore, the proliferation of tumor cells, such as HepG2 cells, BEL-7402 
cells and SGC-7901 cells could be restrained by CKI. Further Studies show that the expression of tumor metastasis 
suppressor gene — nm23 could remarkably be promoted by CKI in BEL-7402 cells, meanwhile in contrast, the expression of 
CD44v6 in BEL-7402 cells could be depressed (Li et al., 2006). Based on these data, CKI could be a complementary drug with 
TACE to inhibit the growth of liver cancer, suppress the tumor metastasis, and improve quality of patients’ life for UHCC.  
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Figure 5: Funnel plot of tumor response (CR+PR). 
A graphical display of the logarithm of odds ratio (OR) plotted against OR. The vertical line indicates that there was no 
publication bias. 
 
    The results show that TACE plus CKI seemed superior to TACE alone for UHCC in respect to patients’ tumor 
response, quality of life and one-year survival. Although quality of included literature are low, the results of this study 
present credible evidence that the administration of CKI plus TACE is worthy of additional study. Hence, larger, longer-term, 
rigorously designed, multi-center, randomized, double-blind, controlled trials are required to fully assess whether CKI plus 
TACE is more outstanding than TACE alone. 
    There are some limitations in this meta-analysis. Due to all literatures we found were of poor methodological 
quality, the definite conclusions could not be made base on our data. All included trials mentioned “randomized,” but all of 
them did not describe the information of randomization sequence generation, allocation concealment, and blinding. All 
included literatures did not report the withdrawals and dropouts. We found that the number of patients in experimental group 
and control group has no change before and after treatment. So it is possible that there are no withdrawals and dropouts 
happened. However, the evaluation of one-year survival should be interpreted with caution. 
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